{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:15:43Z","timestamp":1769598943192,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jad.2021.08.149","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T01:05:10Z","timestamp":1630631110000},"page":"476-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparison of the effect of citalopram, bupropion, sertraline, and tricyclic antidepressants on QTc: A cross-sectional study"],"prefix":"10.1016","volume":"296","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5735-7973","authenticated-orcid":false,"given":"Craig M.","family":"Straley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Sochacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea N.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-912X","authenticated-orcid":false,"given":"Terrence Bradley","family":"Baugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2021.08.149_bib0001","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3109\/15563650.2011.635149","article-title":"2010 annual report of the American association of poison control centers\u2019 national poison data system (NPDS): 28th annual report","volume":"49","author":"Bronstein","year":"2011","journal-title":"Clin. Toxicol. Phila"},{"key":"10.1016\/j.jad.2021.08.149_bib0002","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bmj.325.7376.1332","article-title":"Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data","volume":"325","author":"Buckley","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2021.08.149_bib0003","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/bmj.f288","article-title":"QT interval and antidepressant use: a cross sectional study of electronic health records","volume":"346","author":"Castro","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2021.08.149_bib0004","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/10673220903129798","article-title":"The use of selective serotonin reuptake inhibitors in elderly patients","volume":"17","author":"Chemali","year":"2009","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.149_bib0005","unstructured":"Champely, S., Ekstrom, C., Dalgaard, P., Gill, J., Weibelzahl, S., Anandkumar, A., Ford, C., Volcic, R., De Rosario, H., De Rosario, M.H., 2018. Package \u2018pwr.\u2019 R Package Version 1."},{"key":"10.1016\/j.jad.2021.08.149_bib0006","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jad.2019.02.060","article-title":"Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting","volume":"250","author":"Cr\u00e9peau-Gendron","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.08.149_bib0007","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jelectrocard.2019.06.009","article-title":"QT correction in atrial fibrillation - measurement revisited","volume":"56","author":"Dash","year":"2019","journal-title":"J. Electrocardiol."},{"key":"10.1016\/j.jad.2021.08.149_bib0009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jagp.2016.11.010","article-title":"Unintended consequences of adjusting citalopram prescriptions following the 2011 FDA warning","volume":"25","author":"Gerlach","year":"2017","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.149_bib0010","first-page":"16","article-title":"Review of the cardiovascular effects of heterocyclic antidepressants","volume":"54","author":"Glassman","year":"1993","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.149_bib0011","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8167.2006.00408.x","article-title":"QT interval: how to measure it and what is \u201cnormal","volume":"17","author":"Goldenberg","year":"2006","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"1","key":"10.1016\/j.jad.2021.08.149_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15563650.2013.872791","article-title":"Drugs and other chemicals involved in fatal poisoning in England and Wales during 2000-2011","volume":"52","author":"Handley","year":"2014","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.jad.2021.08.149_bib0013","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1192\/bjp.bp.109.070219","article-title":"Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose","volume":"196","author":"Hawton","year":"2010","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.jad.2021.08.149_bib0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jemermed.2008.06.030","article-title":"Comparison of toxicity of acute overdoses with citalopram and escitalopram","volume":"39","author":"Hayes","year":"2010","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.jad.2021.08.149_bib0015","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/01.JGP.0000219282.32915.a4","article-title":"Gender disparities in the treatment of late-life depression: qualitative and quantitative findings from the IMPACT trial","volume":"14","author":"Hinton","year":"2006","journal-title":"Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.149_bib0016","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1345\/aph.1C481","article-title":"Bupropion overdose: QTc prolongation and its clinical significance","volume":"37","author":"Isbister","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jad.2021.08.149_bib0017","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1081\/CLT-120037428","article-title":"Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose","volume":"42","author":"Isbister","year":"2004","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"10.1016\/j.jad.2021.08.149_bib0018","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1081\/CLT-120028747","article-title":"Comparative toxicity of citalopram and the newer antidepressants after overdose","volume":"42","author":"Kelly","year":"2004","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"10.1016\/j.jad.2021.08.149_bib0019","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2021.08.149_bib0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/10401239409148989","article-title":"The cardiovascular effects of bupropion and nortriptyline in depressed outpatients","volume":"6","author":"Kiev","year":"1994","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.149_bib0021","series-title":"The Use of Medicines in the United States: Review of 2011","author":"Kleinrock","year":"2012"},{"key":"10.1016\/j.jad.2021.08.149_bib0022","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00414-005-0528-x","article-title":"Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data","volume":"119","author":"Koski","year":"2005","journal-title":"Int. J. Legal Med."},{"key":"10.1016\/j.jad.2021.08.149_bib0023","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/pds.2181","article-title":"Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia","volume":"20","author":"Leonard","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jad.2021.08.149_bib0024","doi-asserted-by":"crossref","first-page":"10B","DOI":"10.1016\/0002-9149(93)90033-9","article-title":"Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms","volume":"72","author":"Morganroth","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jad.2021.08.149_bib0025","doi-asserted-by":"crossref","first-page":"23B","DOI":"10.1016\/0002-9149(93)90036-C","article-title":"Measurement of the QT interval and the risk associated with QTc interval prolongation: a review","volume":"72","author":"Moss","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jad.2021.08.149_bib0026","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/01.CIR.84.3.1136","article-title":"The long QT syndrome. Prospective longitudinal study of 328 families","volume":"84","author":"Moss","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jad.2021.08.149_bib0027","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4037\/NCI.0b013e31822db49d","article-title":"QTc prolongation in the intensive care unit: a review of offending agents","volume":"22","author":"Nelson","year":"2011","journal-title":"AACN Adv. Crit. Care"},{"key":"10.1016\/j.jad.2021.08.149_bib0028","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0278-5846(82)80181-4","article-title":"Kinetics of citalopram in man; plasma levels in patients","volume":"6","author":"Over\u00f8","year":"1982","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.149_bib0029","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/14740338.2016.1199681","article-title":"An analysis of QTc prolongation with atypical antipsychotic medications and selective serotonin reuptake inhibitors using a large ECG record database","volume":"15","author":"Park","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2021.08.149_bib0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199910000-00004","article-title":"Cardiac safety of citalopram: prospective trials and retrospective analyses","volume":"19","author":"Rasmussen","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.08.149_bib0031","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1176\/appi.ajp.2016.15111444","article-title":"Outcomes of citalopram dosage risk mitigation in a veteran population","volume":"173","author":"Rector","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.149_bib0032","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","article-title":"QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients","volume":"355","author":"Reilly","year":"2000","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.jad.2021.08.149_bib0033","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1113\/JP270526","article-title":"Predicting drug-induced QT prolongation and torsades de pointes","volume":"594","author":"Roden","year":"2016","journal-title":"J. Physiol."},{"key":"10.1016\/j.jad.2021.08.149_bib0034","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/15563650.2019.1699658","article-title":"Clinical characteristics and outcomes associated with bupropion overdose: a Canadian perspective","volume":"58","author":"Stewart","year":"2020","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.jad.2021.08.149_bib0035","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1185\/03007995.2013.840568","article-title":"QT interval prolongation and the risk of torsades de pointes: essentials for clinicians","volume":"29","author":"Trinkley","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2021.08.149_bib0036","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","article-title":"Medication augmentation after the failure of SSRIs for depression","volume":"354","author":"Trivedi","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2021.08.149_bib0037","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.149_bib0046","unstructured":"US Food and Drug Administration. (2005). Guidance for industry. E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http:\/\/www.fda.gov\/cder\/guidance\/6922fnl.pdf. Accessed 10\/5\/2020."},{"key":"10.1016\/j.jad.2021.08.149_bib0038","series-title":"FDA Drug Safety Communication: Abnormal Heart Rhythms Associated with High Doses of Celexa (Citalopram Hydrobromide)","year":"2011"},{"key":"10.1016\/j.jad.2021.08.149_bib0039","first-page":"1","article-title":"mice\u00a0: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.jad.2021.08.149_bib0040","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1176\/appi.psy.45.5.371","article-title":"Tricyclic antidepressants, QT interval prolongation, and torsade de pointes","volume":"45","author":"Vieweg","year":"2004","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jad.2021.08.149_bib0041","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/11318880-000000000-00000","article-title":"Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly","volume":"26","author":"Vieweg","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jad.2021.08.149_bib0042","first-page":"174","article-title":"Comparison of the effects of bupropion and amitriptyline on cardiac conduction in depressed patients","volume":"44","author":"Wenger","year":"1983","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.08.149_bib0043","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/JCP.0000000000000631","article-title":"Comparative risk of ventricular arrhythmia and sudden cardiac death across antidepressants in patients with depressive disorders","volume":"37","author":"Wu","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.08.149_bib0044","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/01.md.0000085057.63483.9b","article-title":"Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors","volume":"82","author":"Zeltser","year":"2003","journal-title":"Med. Baltim."},{"key":"10.1016\/j.jad.2021.08.149_bib0045","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1176\/appi.ajp.2013.12030408","article-title":"Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg","volume":"170","author":"Zivin","year":"2013","journal-title":"Am. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272100954X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272100954X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T02:26:06Z","timestamp":1759026366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503272100954X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":45,"alternative-id":["S016503272100954X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2021.08.149","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the effect of citalopram, bupropion, sertraline, and tricyclic antidepressants on QTc: A cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2021.08.149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}